. Author manuscript; available in PMC: 2020 Nov 5.

Published in final edited form as: J Urol. 2014 Aug 20;193(2):473–478. doi: 10.1016/j.juro.2014.08.083

Table 3.

Biopsy pathology for the 5 patients who were diagnosed with PCa at fusion targeted re-biopsy. Right side of the table (shaded) demonstrates which biopsy modality detected (+) the core with the highest Gleason sum.

			Re-Biopsy Results				Targeted Biopsies		Random 12-core Biopsies
Pt	Stage	PSA [ng/ml]	Cores Sampled (n)	Cores Positive (n)	Highest Gleason Sum	Percent of Core(s) Involved (%)	Old ASAP, Re-Targeted	Target, Other	Same Sextant as Old ASAP	Random, Other
1	cT1c	8.13	18	3	3+3=6	30, 5, 5	+	−	+	−
2	cT1c	8.63	16	3	3+3=6	30, 10, 10	+	+	+	−
3	cT1c	11.30	21	1	3+3=6	20	−	−	−	+
4	cT1c	0.83^†	20	2	3+3=6	8, 5	+	−	−	−
5	cT1c	11.49	20	4	3+4=7^*	8, 5, 5, 5	+	−	−	−
Detection Rate							4/5 (80%)	1/5 (20%)	2/5 (40%)	1/5 (20%)

^†

On 5-ARI.

This patient had Gleason 3+4=7 PCa in 8% of one targeted core, with the remaining 3 cores as Gleason 3+3=6 in 5% of each core.